BioMarin Pharmaceutical
Categories
#1142
Rank
$16.01B
Marketcap
United States
Country
Christopher Starr (Founder)
Grant Denison Jr. (Founder)
Pharma and Life Sciences
Summary
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates.
Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany.
History
1997: BioMarin (BMRN) is based in San Rafael, California, and was founded. When BioMarin first opened its doors+, treatment of rare diseases was as rare as the conditions themselves.
1999: BioMarin was listed on the NASDAQ stock exchange.
2009: BioMarin acquired Huxley Pharmaceuticals Inc.
Mission
To bring new treatments to market that will make a big impact on small patient populations. These patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide.
Vision
At BioMarin, we view ourselves as a team of pioneers willing to take risks in the quest to find new solutions to address the biggest challenges in rare diseases, and motivated by the desire to help improve the lives of patients with unmet medical needs.
Key Team
Alan Lewis (Board Member)
Alan Lewis (Board Member)
David E.I. Pyott, M.D. (Hon.) (Board Member)
Aman Bains (CMO Sr. Associate)
Elaine J. Heron (Board Member)
Andrea L. Acosta (Group Vice President and Chief Accounting Officer)
Elizabeth McKee Anderson (Board Member)
Becky Stamps (Sr. Executive Coordinator To Chief Scientific Strategy Officer)
Kenneth Bate (Board Member)
Brian R. Mueller (Executive Vice President and Chief Financial Officer)
Mike Grey (Board Member)
Charles Greg Guyer (Chief Technical Officer and Executive Vice President)
Randy Meier (Board Member)
Cybelle Mandigo (External Manufacturing (CMO) Manager)
Richard A. Meier (Board Member)
Christopher Starr (Founder)
Robert A Baffi (Special Advisor To The Chairman & Chief Executive Officer)
Grant Denison Jr. (Founder)
Jean Jacques Bienaime (CEO)
Recognition and Awards
References
https://en.wikipedia.org/wiki/BioMarin_Pharmaceutical
https://www.zippia.com/biomarin-pharmaceutical-careers-1531/
https://www.crunchbase.com/organization/biomarin-pharmaceutical
https://sec.report/CIK/0001004980
https://companiesmarketcap.com/largest-companies-by-revenue/
https://www.linkedin.com/company/biomarin
https://finance.yahoo.com/quote/BMRN/
https://www.forbes.com/companies/biomarin-pharmaceutical/
https://www.reuters.com/companies/BMRN.OQ
Christopher Starr (Founder)
Grant Denison Jr. (Founder)
Pharma and Life Sciences